Patents by Inventor Carlos F. Ibanez

Carlos F. Ibanez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glial cell line-derived neurotrophic factor receptors
    Publication number: 20040126819
    Abstract: Receptors for Glial Cell Line-Derived Neurotrophic Factor (GDNF), their cellular expression, isolation, biochemical characterization, and sequences are disclosed. c-RET is disclosed as one receptor for GDNF; additional novel receptors are also disclosed. The preparation of monoclonal antibodies directed against GDNF is also disclosed.
    Type: Application
    Filed: September 26, 2003
    Publication date: July 1, 2004
    Inventors: Carlos F. Ibanez, Miles Trupp, Mart Saarma, Hannu Sariola, Urmas Arumae, Petro Suvanto
  • Assays using glial cell line-derived neurotrophic factor receptors
    Patent number: 6696259
    Abstract: Receptors for Glial Cell Line-Derived Neurotrophic Factor (GDNF), their cellular expression, isolation, biochemical characterization, and sequences are disclosed. c-RET is disclosed as one receptor for GDNF; additional novel receptors are also disclosed. The preparation of monoclonal antibodies directed against GDNF is also disclosed.
    Type: Grant
    Filed: May 22, 1997
    Date of Patent: February 24, 2004
    Assignee: Licentia Ltd.
    Inventors: Carlos F. Ibanez, Miles Trupp, Mart Saarma, Hannu Sariola, Urmas Arumäe, Petro Suvanto
  • Bioassay using ALK-7, a novel serine threonine kinase receptor
    Patent number: 5976815
    Abstract: The present invention relates, in general, to a novel serine threonine kinase receptor, ALK-7. In particular, the present invention relates to nucleic acid molecules coding for ALK-7; ALK-7 polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to ALK-7; hybridomas containing the antibodies; nucleic acid probes for the detection of ALK-7 nucleic acid; a method of detecting ALK-7 nucleic acid or polypeptide in a sample; and kits containing nucleic acid probes or antibodies. This invention further relates to bioassays using the nucleic acid sequence, receptor protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with neurodegenerative disease. Therapeutic uses for ALK-7 are also provided. This invention also relates to ligands, agonists, and antagonists of the ALK-7 receptor, and diagnostic and therapeutic uses thereof.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: November 2, 1999
    Assignee: Carlos F. Ibanez
    Inventors: Carlos F. Ibanez, Mikael Ryden, Henrik Jornvall
  • Serine threonine kinase receptor, alk-7
    Patent number: 5891638
    Abstract: The present invention relates, in general, to a novel serine threonine kinase receptor, ALK-7. In particular, the present invention relates to nucleic acid molecules coding for ALK-7; ALK-7 polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to ALK-7; hybridomas containing the antibodies; nucleic acid probes for the detection of ALK-7 nucleic acid; a method of detecting ALK-7 nucleic acid or polypeptide in a sample; and kits containing nucleic acid probes or antibodies. This invention further relates to bioassays using the nucleic acid sequence, receptor protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with neurodegenerative disease. Therapeutic uses for ALK-7 are also provided. This invention also relates to ligands, agonists, and antagonists of the ALK-7 receptor, and diagnostic and therapeutic uses thereof.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: April 6, 1999
    Assignee: Carlos F. Ibanez
    Inventors: Carlos F. Ibanez, Mikael Ryden, Henrik Jornvall
  • Antibodies that specifically bind to ALK-7, a novel serine threonine kinase receptor
    Patent number: 5811245
    Abstract: The present invention relates, in general, to a novel serine threonine kinase receptor, ALK-7. In particular, the present invention relates to nucleic acid molecules coding for ALK-7; ALK-7 polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to ALK-7; hybridomas containing the antibodies; nucleic acid probes for the detection of ALK-7 nucleic acid; a method of detecting ALK-7 nucleic acid or polypeptide in a sample; and kits containing nucleic acid probes or antibodies. This invention further relates to bioassays using the nucleic acid sequence, receptor protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with neurodegenerative disease. Therapeutic uses for ALK-7 are also provided. This invention also relates to ligands, agonists, and antagonists of the ALK-7 receptor, and diagnostic and therapeutic uses thereof.
    Type: Grant
    Filed: February 24, 1997
    Date of Patent: September 22, 1998
    Assignee: Carlos F. Ibanez
    Inventors: Carlos F. Ibanez, Mikael Ryden, Henrik Jornvall
  • Serine threonine kinase receptor, ALK-7
    Patent number: 5789565
    Abstract: The present invention relates, in general, to a novel serine threonine kinase receptor, ALK-7. In particular, the present invention relates to nucleic acid molecules coding for ALK-7; ALK-7 polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to ALK-7; hybridomas containing the antibodies; nucleic acid probes for the detection of ALK-7 nucleic acid; a method of detecting ALK-7 nucleic acid or polypeptide in a sample; and kits containing nucleic acid probes or antibodies. This invention further relates to bioassays using the nucleic acid sequence, receptor protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with neurodegenerative disease. Therapeutic uses for ALK-7 are also provided. This invention also relates to ligands, agonists, and antagonists of the ALK-7 receptor, and diagnostic and therapeutic uses thereof.
    Type: Grant
    Filed: February 24, 1997
    Date of Patent: August 4, 1998
    Assignee: Carlos F. Ibanez
    Inventors: Carlos F. Ibanez, Mikael Ryden, Henrik Jornvall